Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Inventors:
John Zoltan Sulliva-Bolyai, Benjamin Alexander Mayes, Douglas Lytle Mayers, Xiao-Jian Zhou, Adel M. Moussa, Alistair James Stewart, Sindhura Ganga, Clinton Scott Shultz, Alfred Lee
Abstract: Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, Z1, Z2, Z3, Z4, V, W, X, Ar, R1 and R2 are as described herein.
Type:
Application
Filed:
November 25, 2014
Publication date:
February 2, 2017
Applicant:
IDENIX PHARMACEUTICALS LLC
Inventors:
Cyril B. Dousson, David Dukhan, Christophe Claude Parsy
Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Z1 Z2, Z3, Z4, V, W, X, Y, Ar, R1 and R2 are as described herein.
Type:
Application
Filed:
November 19, 2014
Publication date:
September 29, 2016
Applicant:
IDENIX PHARMACEUTICALS LLC
Inventors:
Adel M. Moussa, Alistair James Stewart, Benjamin Alexander Mayes
Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula I: or a pharmaceutically acceptable salt, solvate, tautomeric or polymorphic form thereof.
Type:
Grant
Filed:
September 11, 2012
Date of Patent:
August 2, 2016
Assignee:
IDENIX PHARMACEUTICALS LLC
Inventors:
Dominique Surleraux, Cyril B. Dousson, Gilles Gosselin, David Dukhan, Claire Pierra, Jerome Peyronnet
Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
Type:
Grant
Filed:
February 9, 2012
Date of Patent:
May 31, 2016
Assignee:
Idenix Pharmaceuticals LLC
Inventors:
Christophe Claude Parsy, Francois-Rene Alexandre, Thierry Convard, Dominique Surleraux
Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.
Type:
Grant
Filed:
March 3, 2014
Date of Patent:
April 12, 2016
Assignees:
IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUES
Inventors:
Alistair James Stewart, Adel M. Moussa, Benjamin Alexander Mayes, Francois-Rene Alexandre, Dominique Surleraux, Christophe Claude Parsy, Claire Pierra, David Dukhan, Gilles Gosselin
Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.
Type:
Grant
Filed:
December 17, 2013
Date of Patent:
December 15, 2015
Assignees:
Idenix Pharmaceuticals LLC, Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences et Techniques
Inventors:
Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, Gilles Gosselin
Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Y, Z, A, RC and RD are as described herein.
Type:
Grant
Filed:
September 26, 2013
Date of Patent:
November 24, 2015
Assignee:
IDENIX PHARMACEUTICALS LLC
Inventors:
Benjamin Alexander Mayes, Adel M. Moussa
Abstract: Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2?,4?-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2?,4?-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.
Type:
Grant
Filed:
April 1, 2014
Date of Patent:
November 17, 2015
Assignee:
IDENIX PHARMACEUTICALS LLC
Inventors:
Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
Type:
Grant
Filed:
November 13, 2012
Date of Patent:
November 17, 2015
Assignee:
Idenix Pharmaceuticals LLC
Inventors:
Cyril B. Dousson, David Dukhan, Christophe Claude Parsy, Claire Pierra, Francois-Rene Alexandre, Guillaume Brandt, Daniel Da Costa, Houcine Rahali, Jean-Laurent Paparin, Michel Derock, Thierry Convard, Dominique Surleraux
Abstract: This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.
Type:
Grant
Filed:
May 2, 2014
Date of Patent:
November 17, 2015
Assignee:
Idenix Pharmaceuticals, LLC
Inventors:
Richard Storer, Gilles Gosselin, David Dukhan, Frederic Leroy